Provided by Tiger Trade Technology Pte. Ltd.

Mesoblast

16.76
-0.6800-3.90%
Pre-market: 16.760.00000.00%04:00 EDT
Volume:173.73K
Turnover:2.91M
Market Cap:2.17B
PE:-37.75
High:16.95
Open:16.92
Low:16.63
Close:17.44
52wk High:21.50
52wk Low:12.66
Shares:129.69M
Float Shares:84.12M
Volume Ratio:0.72
T/O Rate:0.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4440
EPS(LYR):-0.8457
ROE:-9.86%
ROA:-4.11%
PB:3.82
PE(LYR):-19.82

Loading ...

State Street Group Ceases to Be Substantial Holder in Mesoblast

TIPRANKS
·
Aug 07

State Street Group Cuts Mesoblast Stake Below Substantial Holder Threshold

TIPRANKS
·
Aug 03

Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch

GlobeNewswire
·
Jul 30

Mesoblast - Q4 Ryoncil Net Revenue US$36 Mln

THOMSON REUTERS
·
Jul 30

Mesoblast Stock And 2 Australian Founder Led Companies Worth Watching

Simply Wall St.
·
Jul 27

State Street Exits Substantial Holding in Mesoblast

TIPRANKS
·
Jul 24

Mesoblast CEO Boosts Stake as Company Files New Equity Announcements

TIPRANKS
·
Jul 21

Mesoblast CEO Boosts Stake in Company With AU$2.7 Million Exercise of Options

MT Newswires Live
·
Jul 21

Mesoblast - CEO Exercises 1.9 Mln Options at A$1.45 Each for A$2.73 Mln

THOMSON REUTERS
·
Jul 21

Mesoblast - CEO Increases Shareholding to 80.8 Mln Shares

THOMSON REUTERS
·
Jul 21

Mesoblast Expands Ordinary Share Base Through Conversion of Unquoted Securities

TIPRANKS
·
Jul 14

Mesoblast Seeks ASX Quotation for 2.25 Million Incentive Shares

TIPRANKS
·
Jul 14

Mesoblast Issues 8.2 Million Unquoted Employee Options

TIPRANKS
·
Jul 14

Mesoblast Achieves Patient Treatment Target in Phase 3 Trial of Chronic Lower Back Pain

MT Newswires Live
·
Jul 14

Mesoblast Hits 300‑Patient Milestone in Pivotal Back Pain Trial

TIPRANKS
·
Jul 14

Mesoblast reported Q4 Ryoncil net revenue of $36M

TIPRANKS
·
Jul 13

Mesoblast rises 6.2%

TIPRANKS
·
Jul 13

Mesoblast Reports $36 Million Ryoncil Revenue for Fiscal Q4

MT Newswires Live
·
Jul 10

Mesoblast's Fiscal Fourth Quarter Net Revenue from MSC Therapy Product Sales Beats Jefferies Forecast

MT Newswires Live
·
Jul 10

Mesoblast Says Ryoncil Net Revenue Exceeds Expectations; Shares Up 5%

MT Newswires Live
·
Jul 10